TICKERNERD
Menu
CLDICLDIHealthcare · Biotechnology

CLDI Stock Forecast: Calidi Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$0.64

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 23 Oct 2026 — in the weakest quartile.

Market cap
$2.3M
Ticker Nerd rank
24/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$4.2M
Net income−$4.2M
Free cash flow−$4.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

CLDI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Calidi Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Oct 2026
24/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
87
Issuance
53
Growth
42
Volatility
26
Revisions
25
Value
15
Quality
14
Momentum
2

Size (98): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLDI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLDI, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 June 2024Ladenburg ThalmannInitiatesBuy—
15 May 2024BairdMaintainsOutperform—
21 Mar 2024BairdMaintainsOutperform—
21 Mar 2024HC Wainwright & Co.MaintainsBuy—
22 Nov 2023HC Wainwright & Co.InitiatesBuy—
9 Oct 2023BairdInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CLDI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Estimates

CLDI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Calidi Biotherapeutics, Inc. (CLDI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.8×

Cheaper than 71% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 84% of US stocks

EV / EBITDA
0.0×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−672.2%

Higher than 2% of US stocks

Return on assets
−134.8%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Calidi Biotherapeutics, Inc. (CLDI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Calidi Biotherapeutics, Inc. has a market value of $2.3M and an enterprise value of −$443K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$17.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$17.8M.

  • Shares outstanding: 179,812.

  • Trailing P/E: 0.8×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Calidi Biotherapeutics, Inc. employs 29 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Oct 2026

Data provided by Twelve Data

Peers

CLDI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLDICalidi Biotherapeutics, Inc.$2.3M24
DCOYDecoy Therapeutics, Inc.$2.3M19
VIVSVivoSim Labs, Inc.$2.5M32
BRTXBioRestorative Therapies, Inc.$2.2M7
ONCOOnconetix, Inc.$2.2M15
ELABPMGC Holdings, Inc.$2.2M3
REVBRevelation Biosciences, Inc.$2.2M9

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Calidi Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLDI news & analysis

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

GlobeNewsWire · 19 Oct 2026positive

Calidi Biotherapeutics announced it will present two posters at the ESMO Congress 2026 in Madrid, scheduled for October 23–27. The presentations will feature its RedTail platform and advances in CLD-401 and its in situ TCE platform.

Why it matters — The posters will provide updates on Calidi’s therapeutic programs and platform at a major oncology congress.

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

GlobeNewsWire · 25 Sept 2026negative

Calidi Biotherapeutics announced that on September 21, 2026, it received a notice from NYSE American stating the Company is not in compliance with continued listing standards requiring stockholders' equity of at least $4.0 million after reported losses in three of its four most recent fiscal years. The notice also indicated the Company is not currently eligible for any exemption under Section 1003(a) of the Company Guide.

Why it matters — CLDI watchers would care because the notice signals a potential listing-compliance issue that could affect the Company's continued trading on NYSE American.

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

GlobeNewsWire · 17 Sept 2026neutral

Calidi Biotherapeutics announced a registered direct offering of 1,025,640 shares of its common stock at $1.17 per share, for total proceeds of approximately $1.2 million. The offering, made with accredited investors and/or qualified institutional buyers, is expected to close on or about September 18, 2026, subject to customary closing conditions.

Why it matters — The registered direct offering provides Calidi with additional capital financing, which CLDI watchers may note as a share-count increase and potential dilution event.

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Calidi Biotherapeutics announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14–16, 2026 at the Lotte New York Palace Hotel. The company made the announcement on September 8, 2026.

Why it matters — A CLDI watcher would care because company participation in a prominent investment conference indicates potential opportunities for investor engagement and visibility within the financial community.

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 13 Aug 2026positive

Calidi Biotherapeutics announced its second quarter 2026 financial results and recent business highlights. The company reported receiving positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study, targeting first patient dosing in Q1 2027.

Why it matters — This regulatory milestone for CLD-401 advances Calidi's pipeline toward its first-in-human study and provides investors with a clearer timeline for clinical development.

FAQ

Frequently asked questions about CLDI stock

How does Ticker Nerd's model rank CLDI?

As at 23 Oct 2026, Calidi Biotherapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the CLDI stock forecast for 2030?

No analyst covering Calidi Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDI are extrapolating price history, which says nothing about the business.

What does Calidi Biotherapeutics, Inc. do?

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease.

What is the latest news on CLDI?

The most recent item we track (GlobeNewsWire, 19 Oct 2026): "Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026". Calidi Biotherapeutics announced it will present two posters at the ESMO Congress 2026 in Madrid, scheduled for October 23–27. The presentations will feature its RedTail platform and advances in CLD-401 and its in situ TCE platform.

Company

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease. The company’s current programs center on stem cell-based and oncolytic virus platforms designed to transport therapeutic payloads directly into tumors while helping protect them from premature immune clearance. Its portfolio includes product candidates for cancers such as high-grade glioma and solid tumors, reflecting a focus on oncology and precision delivery methods. Calidi Biotherapeutics also works across systemic and localized treatment approaches, using proprietary cell-based technologies to support tumor targeting, immune activation, and controlled payload delivery. Headquartered in San Diego, California, Calidi Biotherapeutics plays a role in the broader biopharmaceutical market as a developer of advanced immuno-oncology and gene therapy solutions.

CEO Dr. Eric E. Poma Ph.D. · 29 employees · United States · https://www.calidibio.com